Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Symmetric Dimethylarginine for Risk Stratification of Cardioembolic Stroke.

Translational stroke research·2026
Same author

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same author

Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

European journal of heart failure·2026
Same author

Comparison of three different hpv self-sampling tools - a subanalysis of the prospective, randomized hannover self-collection study.

Archives of gynecology and obstetrics·2026
Same author

Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trial.

Frontiers in cardiovascular medicine·2026
Same author

Serotonin 5-HT7 receptor signaling modulates inflammatory responses and survival after myocardial infarction.

Journal of translational medicine·2026

Related Experiment Video

Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.

Udo Bavendiek1, Anika Großhennig2, Johannes Schwab3,4

  • 1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

The New England Journal of Medicine
|August 29, 2025
PubMed
Summary

Digitoxin treatment significantly reduced the combined risk of death or heart failure hospitalization in patients with reduced ejection fraction. This study establishes digitoxin as a potential therapy for heart failure management.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Related Experiment Videos

Last Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • The efficacy of digitoxin, a cardiac glycoside, for treating heart failure with reduced ejection fraction (HFrEF) remains unproven.
  • Guideline-directed medical therapy (GDMT) is standard for HFrEF, but additional treatments are needed.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of digitoxin compared to placebo in patients with HFrEF receiving GDMT.
  • To assess the impact of digitoxin on mortality and heart failure hospitalizations.

Main Methods:

  • An international, double-blind, placebo-controlled trial randomized 1240 patients with HFrEF to receive either digitoxin or placebo.
  • Patients had left ventricular ejection fraction ≤40% (NYHA class III-IV) or ≤30% (NYHA class II).
  • The primary outcome was a composite of all-cause death or hospital admission for worsening heart failure.

Main Results:

  • In the modified intention-to-treat population (1212 patients), digitoxin reduced the primary composite outcome by 18% (hazard ratio, 0.82; P=0.03).
  • Over a median of 36 months, digitoxin showed a trend towards lower all-cause mortality (HR, 0.86) and heart failure hospitalizations (HR, 0.85).
  • Serious adverse events were more frequent in the digitoxin group (4.7% vs. 2.8%).

Conclusions:

  • Digitoxin treatment significantly lowered the combined risk of death or heart failure hospitalization in HFrEF patients on GDMT.
  • Digitoxin represents a potential therapeutic option for managing heart failure with reduced ejection fraction.
  • Further research may explore optimal dosing and long-term safety profiles.